FDA Waxman/Hatch “Moot Court” Will Examine Brand/Generic Legal Positions

FDA's chief counsel will be hosting a "moot court" to receive a thorough briefing on the brand and generic industry arguments about the agency's interpretation of the Waxman/Hatch Act